Study of AC-201 in Patients With Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT01276106. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase II Study of AC-201 in Patients With Type 2 Diabetes Mellitus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 24-week randomized placebo-controlled study to investigate the effect of an oral IL-1beta inhibitor AC-201 in patients with type 2 diabetes mellitus already treated on different background diabetes therapies.
Study identification
- NCT ID
- NCT01276106
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 259 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 20 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2010
- Primary completion
- Jan 31, 2012
- Completion
- Feb 29, 2012
- Last update posted
- May 21, 2018
2011 – 2012
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Catalina Research Institute, LLC | Chino | California | — | — |
| National Research Institute | Los Angeles | California | — | — |
| Clinical Research of South Florida | Coral Gables | Florida | — | — |
| Jacksonville Impotence Treatment Center | Jacksonville | Florida | — | — |
| Chicago Clinical Research Institute, Inc. | Chicago | Illinois | — | — |
| Clinical Investigation Specialists, Inc. | Gurnee | Illinois | — | — |
| Midwest Institute for Clinical Research, Inc. | Indianapolis | Indiana | — | — |
| L-MARC Research Center | Louisville | Kentucky | — | — |
| New Orleans Center for Clinical Research | New Orleans | Louisiana | — | — |
| Sterling Research Group, Ltd | Cincinnati | Ohio | — | — |
| PriMed Clinical Research | Kettering | Ohio | — | — |
| National Clinical Research-Richmond, Inc. | Richmond | Virginia | — | — |
| Rainier Clinical Research Center, Inc. | Renton | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01276106, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2018 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01276106 live on ClinicalTrials.gov.